抗体受託製造市場：製造される抗体タイプ別、使用される発現システムタイプ別、事業規模別、地域別

世界の抗体受託製造の市場規模は、2035年までの予測期間中に10%のCAGRで拡大し、現在の166億米ドルから2035年までに470億米ドルに成長すると予測されています。

市場セグメンテーションでは、市場規模および機会分析を以下のパラメータで区分しています：

製造される抗体タイプ別

• モノクローナル
• 二重特異性

使用される発現システムタイプ別

• 哺乳類
• 微生物

事業規模別

• 臨床
• 商業

地域別

• 北米
• 欧州
• アジア
• ラテンアメリカ
• 中東・北アフリカ

抗体医薬品受託製造市場：成長と動向

近年、受託製造業者はバイオ医薬品市場全体にとって不可欠な存在となっています。この動向は抗体製造市場でも人気を集めており、開発企業が抗体製造要件を受託サービス・プロバイダーに委託するケースが増えています。これは、このような第三者サービス・プロバイダーを採用することで、全体的な製造コストの削減や市場投入までの時間の短縮など、さまざまな利点が得られるためと考えられます。実際、この領域に携わる抗体製造企業は、治療用抗体の全体的な需要に対応するため、他の企業と積極的に協力し、既存の能力や能力を拡大しています。

1986年にOrthoclone OKT3（R）が承認されて以来、モノクローナル抗体は現代ヘルスケアの重要な一部となっています。実際、モノクローナル抗体はバイオ医薬品産業の屋台骨であると考える専門家もいます。その高い特異性と良好な安全性プロファイルにより、抗体ベースの介入は現在、生物製剤受託製造市場の最大クラスを構成しています。二重特異性抗体や抗体フラグメントベースの製品など、先進的な変異体が着実に普及しつつあるため、この動向は近い将来も変わりそうにないです。さらに、高度なサプライチェーン要件など、生物製剤の開発・製造に関連する従来の課題が、抗体製造業務のアウトソーシングをさらに後押ししています。

抗体受託製造市場：主要インサイト

当レポートでは、抗体受託製造市場の現状を掘り下げ、業界内の潜在的な成長機会を特定しています。主な調査結果は以下の通りです：

• 現在、125社以上の受託製造業者が世界中で抗体製造サービスを提供していると主張しており、サービスプロバイダーの74%が商業規模でモノクローナル抗体を製造しています。
• 現在の市場情勢は断片化されており、大手企業と新規参入企業の両方が存在します。これらのほとんどは北米を拠点とする中堅企業（43％）です。
• この分野で競合優位性を獲得するため、利害関係者はそれぞれのポートフォリオを強化するために、既存の能力を積極的にアップグレードし、新たな能力を追加しています。
• 能力を向上させ、設備をアップグレードするための継続的な努力は、新製品開発イニシアチブの基準となる業界ベンチマークの確立につながっています。

• この領域における利害関係者の関心の高まりは、提携活動の増加からも明らかであり、提携のほとんどは抗体製造に焦点を当てています。
• この研究分野に関するコアコンピタンスを強化するため、CMOは既存のインフラをアップグレードし、それぞれの製造能力を拡大するために積極的に投資しています。
• 世界の抗体受託製造能力は様々な地域に分散しているが、その55％以上は北米の製造施設にあります。
• 様々な開発段階で評価されている抗体ベースの医薬品・治療薬候補がいくつかあることから、今後10年間でこうした製品の需要は大幅に増加すると予想されます。
• 抗体製造市場は、2035年までCAGR 10%で成長する可能性が高いです。現在、市場シェアの大半を北米が占め、次いで欧州が続いています。

抗体受託製造市場：主要セグメント

製造される抗体タイプ別では、市場はモノクローナル抗体と二重特異性抗体に区分されます。現在のところ、モノクローナル抗体セグメントが世界の抗体受託製造市場で最大のシェアを占めています。しかし、現在では治療用の二重特異性抗体の開発に注力する企業が増えています。

使用される発現システムタイプ別では、市場は哺乳類発現系と微生物発現系に区分されます。現在、世界の抗体受託製造市場で最も高い割合を占めているのは哺乳類発現システムであり、これは哺乳類発現システムによって抗体がより高い生物学的活性と結合親和性を示すためです。

事業規模別では、市場は臨床規模と商業規模に区分されます。現在、世界の抗体受託製造市場では、抗体の商業生産に対する需要の増加により、商業規模が最大のシェアを占めています。

主要地域別に見ると、市場は北米、欧州、アジア、ラテンアメリカ、中東・北アフリカに区分されます。現在、北米が抗体受託製造市場を独占しており、最大の収益シェアを占めています。また、アジアの市場は今後、より高いCAGRで成長する可能性が高いです。

当レポートでは、世界の抗体受託製造市場について調査し、市場の概要とともに、製造される抗体タイプ別、使用される発現システムタイプ別、事業規模別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 調査手法

第3章 経済的およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

• 章の概要
• 抗体の概念
• 抗体の構造
• 抗体アイソタイプ
• 抗体の作用機序
• 抗体の種類
• 契約製造の概要
• バイオ医薬品業界におけるアウトソーシングの必要性
• 製造サービスのアウトソーシングのメリット

第6章 市場情勢

• 章の概要
• 抗体受託製造業者：市場情勢

第7章 企業競争力分析

第8章 詳細な企業プロファイル

• 章の概要
• AGC Biologics
• Aldeveron
• Emergent Biosolutions
• Eurofins CDMO
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Novasep
• Pierre Fabre
• Samsung Biologics
• Synthon
• Thermo Fisher Scientific

第9章 企業プロファイル一覧

• 章の概要
• ABL
• Abzena
• Allele Biotechnology &Pharmaceuticals
• Alvotech
• Antibody Production Services
• Arabio
• Bharat Serums and Vaccines
• Boehringer Ingelheim
• Glenmark Pharmaceuticals
• MilliporeSigma
• Siam Bioscience

第10章 ケーススタディ：小分子と大分子（生物製剤）の薬剤/治療法の比較

• 章の概要
• 小分子および生物製剤

第11章 ベンチマーク分析

• 章の概要
• 調査手法
• 抗体受託製造業者：ベンチマーク分析
• 結論

第12章 パートナーシップとコラボレーション

第13章 最近の拡張

第14章 容量分析

第15章 需要分析

第16章 市場影響分析：促進要因、抑制要因、機会、課題

第17章 世界の抗体受託製造市場

• 章の概要
• 主要な前提と調査手法
• 世界の抗体受託製造市場、歴史的動向（2019年以降）および予測（2035年まで）
• 主要な市場セグメンテーション

第18章 世界の抗体受託製造市場（製造される抗体タイプ別）

第19章 世界の抗体受託製造市場（事業規模別）

第20章 世界の抗体受託製造市場（使用される発現システムタイプ別）

第21章 世界の抗体受託製造市場（主要地域別）

第22章 SWOT分析

第23章 抗体受託製造市場の将来

第24章 エグゼクティブ洞察

第25章 付録2表形式データ

第26章 付録3企業・団体一覧

List of Tables

• Table 5.1 Key Features of Antibody Isotypes
• Table 5.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
• Table 5.3 List of Approved Monoclonal Antibodies
• Table 5.4 Difference between Polyclonal and Monoclonal Antibodies
• Table 6.1 List of Antibody Contract Manufacturers
• Table 6.2 Antibody Contract Manufacturers: Information on Scale of Operation
• Table 6.3 Antibody Contract Manufacturers: Information on Type of Antibody Manufactured
• Table 6.4 Antibody Contract Manufacturers: Information on Type of Expression System Used
• Table 6.5 Antibody Contract Manufacturers: Information on Fill / Finish Services Offered
• Table 8.1 AGC Biologics: Company Overview
• Table 8.2 AGC Biologics: Antibody Contract Manufacturing Service Portfolio
• Table 8.3 AGC Biologics: Recent Development and Future Outlook
• Table 8.4 Aldeveron: Company Overview
• Table 8.5 Aldeveron: Antibody Contract Manufacturing Service Portfolio
• Table 8.6 Aldeveron: Recent Development and Future Outlook
• Table 8.7 Emergent BioSolutions: Company Overview
• Table 8.8 Emergent BioSolutions: Antibody Contract Manufacturing Service Portfolio
• Table 8.9 Emergent BioSolutions: Recent Development and Future Outlook
• Table 8.10 Eurofins CDMO: Company Overview
• Table 8.11 Eurofins CDMO: Antibody Contract Manufacturing Service Portfolio
• Table 8.12 Eurofins CDMO: Recent Development and Future Outlook
• Table 8.13 Fujifilm Diosynth Biotechnologies: Company Overview
• Table 8.14 Fujifilm Diosynth Biotechnologies: Antibody Contract Manufacturing Service Portfolio
• Table 8.15 Fujifilm Diosynth Biotechnologies: Recent Development and Future Outlook
• Table 8.16 KBI Biopharma: Company Overview
• Table 8.17 KBI Biopharma: Antibody Contract Manufacturing Service Portfolio
• Table 8.18 KBI Biopharma: Recent Development and Future Outlook
• Table 8.19 Lonza: Company Overview
• Table 8.20 Lonza: Antibody Contract Manufacturing Service Portfolio
• Table 8.21 Lonza: Recent Development and Future Outlook
• Table 8.22 Nitto Avecia Pharma: Company Overview
• Table 8.23 Nitto Avecia Pharma: Antibody Contract Manufacturing Service Portfolio
• Table 8.24 Nitto Avecia Pharma: Recent Development and Future Outlook
• Table 8.25 Novasep: Company Overview
• Table 8.26 Novasep: Antibody Contract Manufacturing Service Portfolio
• Table 8.27 Novasep: Recent Development and Future Outlook
• Table 8.28 Pierre Fabre: Company Overview
• Table 8.29 Pierre Fabre: Antibody Contract Manufacturing Service Portfolio
• Table 8.30 Pierre Fabre: Recent Development and Future Outlook
• Table 8.31 Samsung Biologics: Company Overview
• Table 8.32 Samsung Biologics: Antibody Contract Manufacturing Service Portfolio
• Table 8.33 Samsung Biologics: Recent Development and Future Outlook
• Table 8.34 Synthon: Company Overview
• Table 8.35 Synthon: Antibody Contract Manufacturing Service Portfolio
• Table 8.36 Synthon: Recent Development and Future Outlook
• Table 8.37 Thermo Fisher Scientific: Company Overview
• Table 8.38 Thermo Fisher Scientific: Antibody Contract Manufacturing Service Portfolio
• Table 8.39 Thermo Fisher Scientific: Recent Development and Future Outlook
• Table 9.1 ABL: Company Overview
• Table 9.2 ABL: Antibody Contract Manufacturing Service Portfolio
• Table 9.3 Absolute Antibody: Company Overview
• Table 9.4 Absolute Antibody: Antibody Contract Manufacturing Service Portfolio
• Table 9.5 Abzena: Company Overview
• Table 9.6 Abzena: Antibody Contract Manufacturing Service Portfolio
• Table 9.7 Allele Biotechnology & Pharmaceuticals: Company Overview
• Table 9.8 Allele Biotechnology & Pharmaceuticals: Antibody Contract Manufacturing Service Portfolio
• Table 9.9 Alvotech: Company Overview
• Table 9.10 Alvotech: Antibody Contract Manufacturing Service Portfolio
• Table 9.11 Antibody Production Services: Company Overview
• Table 9.12 Antibody Production Services (Division of Life Science Group): Antibody Contract Manufacturing Service Portfolio
• Table 9.13 Arabio: Company Overview
• Table 9.14 Arabio: Antibody Contract Manufacturing Service Portfolio
• Table 9.15 Bharat Serums and Vaccines: Company Overview
• Table 9.16 Bharat Serums and Vaccines: Antibody Contract Manufacturing Service Portfolio
• Table 9.17 Boehringer Ingelheim: Company Overview
• Table 9.18 Boehringer Ingelheim: Antibody Contract Manufacturing Service Portfolio
• Table 9.19 Glenmark Pharmaceuticals: Company Overview
• Table 9.20 Glenmark Pharmaceuticals: Antibody Contract Manufacturing Service Portfolio
• Table 9.21 MilliporeSigma: Company Overview
• Table 9.22 MilliporeSigma: Antibody Contract Manufacturing Service Portfolio
• Table 9.23 Siam Bioscience: Company Overview
• Table 9.24 Siam Bioscience: Antibody Contract Manufacturing Service Portfolio
• Table 10.1 Comparison of Strengths and Weaknesses of Small Molecules and Biologics
• Table 10.2 Comparison of Development Characteristics of Small Molecules and Biologics
• Table 11.1 Benchmark Analysis: Information on Peer Groups
• Table 12.1 Antibody Contract Manufacturing: List of Partnerships, Since 2013
• Table 12.2 Antibody Contract Manufacturer Partnerships: Information on Type of Antibodies, Project Scale and Therapeutic Area
• Table 13.1 Antibody Contract Manufacturing: List of Expansions, Since 2017
• Table 13.2 Antibody Contract Manufacturing Expansions: Information on Type of Antibodies
• Table 14.1 Capacity Analysis: Average Capacity for Mammalian Expression System
• Table 14.2 Capacity Analysis: Average Capacity for Microbial Expression System
• Table 14.3 Capacity Analysis: Installed Global Capacity
• Table 14.4 Patent Approval Information of Best-selling Biologics
• Table 26.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
• Table 26.2 Antibody Contract Manufacturers: Distribution by Company Size
• Table 26.3 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region)
• Table 26.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country)
• Table 26.5 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
• Table 26.6 Antibody Contract Manufacturers: Distribution by Scale of Operation
• Table 26.7 Antibody Contract Manufacturers: Distribution by Type of Antibody Manufactured
• Table 26.8 Antibody Contract Manufacturers: Distribution by Expression System Used
• Table 26.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
• Table 26.10 Partnerships: Distribution by Year of Partnership
• Table 26.11 Partnerships: Distribution by Type of Partnership
• Table 26.12 Partnerships: Distribution by Year and Type of Partnership
• Table 26.13 Partnerships: Distribution by Type of Antibody
• Table 26.14 Partnerships: Distribution by Project Scale
• Table 26.15 Partnerships: Distribution by Focus Therapeutic Area
• Table 26.16 Partnerships: Most Active Players
• Table 26.17 Partnerships: Country-wise Distribution
• Table 26.18 Recent Expansions: Distribution by Year of Expansion
• Table 26.19 Recent Expansions: Distribution by Type of Expansion
• Table 26.20 Recent Expansions: Distribution by Type of Antibody
• Table 26.21 Recent Expansions: Distribution by Type of Antibody and Type of Expansion
• Table 26.22 Recent Expansions: Distribution by Location of Facility (Region-wise)
• Table 26.23 Recent Expansions: Distribution by Location of Facility (Country-wise)
• Table 26.24 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
• Table 26.25 Recent Expansions: Most Active Players
• Table 26.26 Recent Expansions: Distribution by Local and International Expansions
• Table 26.27 Capacity Analysis: Distribution by Company Size
• Table 26.28 Capacity Analysis: Distribution by Scale of Operation
• Table 26.29 Capacity Analysis: Distribution by Type of Expression System Used
• Table 26.30 Capacity Analysis: Distribution by Location of Manufacturing Facility
• Table 26.31 Demand Analysis: Annual Demand for Antibodies (in Kilograms)
• Table 26.32 Demand Analysis: Distribution by Scale of Operation (in Kilograms)
• Table 26.33 Demand Analysis: Distribution by Geographical Location
• Table 26.34 Global Antibody Contract Manufacturing Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Table 26.35 Global Antibody Contract Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
• Table 26.36 Global Antibody Contract Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
• Table 26.37 Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured
• Table 26.38 Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (Since 2019) (USD Billion)
• Table 26.39 Antibody Contract Manufacturing Market for Monoclonal Antibodies: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.40 Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (Since 2019) (USD Billion)
• Table 26.41 Antibody Contract Manufacturing Market for Bispecific Antibodies: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.42 Antibody Contract Manufacturing Market: Distribution by Scale of Operation
• Table 26.43 Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (Since 2019) (USD Billion)
• Table 26.44 Antibody Contract Manufacturing Market at Commercial Scale: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.45 Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (Since 2019) (USD Billion)
• Table 26.46 Antibody Contract Manufacturing Market at Clinical Scale: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.47 Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used
• Table 26.48 Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (Since 2019) (USD Billion)
• Table 26.49 Antibody Contract Manufacturing Market for Mammalian Expression System: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.50 Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (Since 2019) (USD Billion)
• Table 26.51 Antibody Contract Manufacturing Market for Microbial Expression System: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.52 Antibody Contract Manufacturing Market: Distribution by Geographical Region
• Table 26.53 Antibody Contract Manufacturing Market in North America: Historical Trends (Since 2019) (USD Billion)
• Table 26.54 Antibody Contract Manufacturing Market in North America: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.55 Antibody Contract Manufacturing Market in Europe: Historical Trends (Since 2019) (USD Billion)
• Table 26.56 Antibody Contract Manufacturing Market in Europe: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.57 Antibody Contract Manufacturing Market in Asia: Historical Trends (Since 2019) (USD Billion)
• Table 26.58 Antibody Contract Manufacturing Market in Asia: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.59 Antibody Contract Manufacturing Market in Latin America: Historical Trends (Since 2019) (USD Billion)
• Table 26.60 Antibody Contract Manufacturing Market in Latin America: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
• Table 26.61 Antibody Contract Manufacturing Market in Middle East and North Africa: Historical Trends (Since 2019) (USD Billion)
• Table 26.62 Antibody Contract Manufacturing Market in Middle East and North Africa: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)

List of Figures

• Figure 2.1 Research Methodology: Project Methodology
• Figure 2.2 Research Methodology: Forecast Methodology
• Figure 2.3 Research Methodology: Robust Quality Control
• Figure 2.4 Research Methodology: Key Market Segmentations
• Figure 3.1 Economic and Other Project Specific Consideration: Lesson Learnt from Past Recessions
• Figure 4.1 Executive Summary: Antibody Contract Manufacturing Market Landscape
• Figure 4.2 Executive Summary: Partnerships
• Figure 4.3 Executive Summary: Recent Expansions
• Figure 4.4 Executive Summary: Capacity Analysis
• Figure 4.5 Executive Summary: Demand Analysis
• Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis
• Figure 5.1 Historical Timelines of Antibodies
• Figure 5.2 Structure of an Antibody
• Figure 5.3 Mechanism of Action of Antibodies
• Figure 5.4 Monoclonal Antibody Production
• Figure 5.5 Symmetric and Asymmetric Bispecific Antibodies
• Figure 5.6 Mechanism of Action of Bispecific Antibodies
• Figure 5.7 Polyclonal Antibody Production
• Figure 5.8 Applications of Polyclonal Antibodies
• Figure 5.9 Types of Third-Party Service Providers
• Figure 6.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
• Figure 6.2 Antibody Contract Manufacturers: Distribution by Company Size
• Figure 6.3 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region)
• Figure 6.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country)
• Figure 6.5 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
• Figure 6.6 Antibody Contract Manufacturers: Distribution by Location Scale of Operation
• Figure 6.7 Antibody Contract Manufacturers: Distribution by Type of Antibody Manufactured
• Figure 6.8 Antibody Contract Manufacturers: Distribution by Type of Expression System Used
• Figure 6.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
• Figure 7.1 Company Competitiveness Analysis: Very Large Antibody Contract Manufacturers based in North America
• Figure 7.2 Company Competitiveness Analysis: Large Antibody Contract Manufacturers based in North America
• Figure 7.3 Company Competitiveness Analysis: Mid-Sized Antibody Contract Manufacturers based in North America
• Figure 7.4 Company Competitiveness Analysis: Small Antibody Contract Manufacturers based in North America
• Figure 7.5 Company Competitiveness Analysis: Very Large Antibody Contract Manufacturers based in Europe
• Figure 7.6 Company Competitiveness Analysis: Large Antibody Contract Manufacturers based in Europe
• Figure 7.7 Company Competitiveness Analysis: Mid-Sized Antibody Contract Manufacturers based in Europe
• Figure 7.8 Company Competitiveness Analysis: Small Antibody Contract Manufacturers based in Europe
• Figure 7.9 Company Competitiveness Analysis: Very Large Antibody Contract Manufacturers based in Asia
• Figure 7.10 Company Competitiveness Analysis: Large Antibody Contract Manufacturers based in Asia
• Figure 7.11 Company Competitiveness Analysis: Mid-Sized Antibody Contract Manufacturers based in Asia
• Figure 7.12 Company Competitiveness Analysis: Small Antibody Contract Manufacturers based in Asia
• Figure 10.1 Small Molecules and Biologics: Historical Trend of FDA Approval, Since 2010
• Figure 10.2 Comparison of Key Characteristics of Small Molecules and Biologics
• Figure 10.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
• Figure 11.1 Benchmark Analysis: Distribution by Region and Company Size
• Figure 11.2 Benchmark Analysis: Small Players Based in North America (Peer Group I)
• Figure 11.3 Benchmark Analysis: Mid-Sized Players Based in North America (Peer Group II)
• Figure 11.4 Benchmark Analysis: Large Players Based in North America (Peer Group III)
• Figure 11.5 Benchmark Analysis: Very Large Players Based in North America (Peer Group IV)
• Figure 11.6 Benchmark Analysis: Small Players Based in Europe (Peer Group V)
• Figure 11.7 Benchmark Analysis: Mid-Sized Players Based in Europe (Peer Group VI)
• Figure 11.8 Benchmark Analysis: Large Players Based in Europe (Peer Group VII)
• Figure 11.9 Benchmark Analysis: Very Large Players Based in Europe (Peer Group VIII)
• Figure 11.10 Benchmark Analysis: Small Players Based in Asia (Peer Group IX)
• Figure 11.11 Benchmark Analysis: Mid-Sized Players Based in Asia (Peer Group X)
• Figure 11.12 Benchmark Analysis: Large Players Based in Asia (Peer Group XI)
• Figure 11.13 Benchmark Analysis: Very Large Players Based in Asia (Peer Group XII)
• Figure 11.14 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
• Figure 12.1 Partnerships: Distribution by Year of Partnership
• Figure 12.2 Partnerships: Distribution by Type of Partnership
• Figure 12.3 Partnerships: Distribution by Year and Type of Partnership
• Figure 12.4 Partnerships: Distribution by Type of Antibody Manufactured
• Figure 12.5 Partnerships: Distribution by Project Scale
• Figure 12.6 Partnerships: Distribution by Target Therapeutic Area
• Figure 12.7 Partnerships: Most Active Players
• Figure 12.8 Partnerships: Country-wise Distribution
• Figure 12.9 Partnerships: Continent-wise Distribution
• Figure 13.1 Recent Expansions: Distribution by Year of Expansion
• Figure 13.2 Recent Expansions: Distribution by Type of Expansion
• Figure 13.3 Recent Expansions: Distribution by Type of Antibody
• Figure 13.4 Recent Expansions: Distribution by Type of Antibody and Type of Expansion
• Figure 13.5 Recent Expansions: Distribution by Location of Facility (Region-wise)
• Figure 13.6 Recent Expansions: Distribution by Location of Facility (Country-wise)
• Figure 13.7 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
• Figure 13.8 Recent Expansions: Most Active Players
• Figure 13.9 Recent Expansions: Distribution by Local and International Expansions
• Figure 14.1 Capacity Analysis: Distribution by Company Size
• Figure 14.2 Capacity Analysis: Distribution by Scale of Operation
• Figure 14.3 Capacity Analysis: Distribution by Type of Expression System Used
• Figure 14.4 Capacity Analysis: Distribution by Location of Manufacturing Facility
• Figure 14.5 Capacity Analysis: Distribution by Location of Manufacturing Facility and Scale of Operation
• Figure 14.6 Capacity Analysis: Distribution by Location of Manufacturing Facility and Company Size
• Figure 15.1 Global Demand for Antibodies, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (in Kilograms)
• Figure 15.2 Global Demand for Antibodies: Distribution by Scale of Operation (in Kilograms)
• Figure 15.3 Global Demand for Antibodies: Distribution by Geographical Region, Till 2035 (in Kilogram)
• Figure 16.1 Antibody Contract Manufacturing: Market Drivers
• Figure 16.2 Antibody Contract Manufacturing: Market Restraints
• Figure 16.3 Antibody Contract Manufacturing: Market Opportunities
• Figure 16.4 Antibody Contract Manufacturing: Market Challenges
• Figure 17.1 Global Antibody Contract Manufacturing Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 17.2 Global Antibody Contract Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
• Figure 17.3 Global Antibody Contract Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
• Figure 18.1 Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured
• Figure 18.2 Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 18.3 Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 19.1 Antibody Contract Manufacturing Market: Distribution by Scale of Operation
• Figure 19.2 Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 19.3 Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 20.1 Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used
• Figure 20.2 Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 20.3 Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 21.1 Antibody Contract Manufacturing Market: Distribution by Geographical Regions
• Figure 21.2 Antibody Contract Manufacturing Market in North America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 21.3 Antibody Contract Manufacturing Market in Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 21.4 Antibody Contract Manufacturing Market in Asia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 21.5 Antibody Contract Manufacturing Market in Latin America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 21.6 Antibody Contract Manufacturing Market in Middle East and North Africa: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• Figure 23.1 Antibody Contract Manufacturing: SWOT Analysis
• Figure 23.2 Comparison of SWOT Factors: Harvey Ball Analysis

ANTIBODY CONTRACT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global antibody contract manufacturing market is estimated to grow from USD 16.6 billion in the current year to USD 47 billion by 2035, at a CAGR of 10% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Antibody Manufactured

• Monoclonal
• Bispecific

Type of Expression System Used

• Mammalian
• Microbial

Scale of Operation

• Clinical
• Commercial

Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa

ANTIBODY CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

In recent years, contract manufacturers have become an integral part of the overall biopharmaceutical market. This trend is also gaining popularity within the antibody manufacturing market, as developers are increasingly outsourcing their antibody manufacturing requirements to contract service providers. This can be attributed to the fact that employing such third-party service providers offers various advantages, such as a reduction in overall production cost and a decrease in time to market. In fact, antibody manufacturing companies engaged in this domain are actively collaborating with other players and expanding their existing capabilities and capacities in order to cater to the overall demand for therapeutic antibodies.

Since the approval of Orthoclone OKT3(R) in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. Owing to their high specificity and the favorable safety profile, antibody-based interventions presently constitute the largest class of biologics contract manufacturing market. This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragment-based products, are steadily gaining traction. Further, the legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements have further boosted the outsourcing antibody production operations.

ANTIBODY CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the antibody contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Presently, over 125 contract manufacturers claim to offer services for antibody manufacturing across the globe; 74% of the service providers manufacture monoclonal antibodies at a commercial scale.
• The current market landscape is fragmented, featuring the presence of both large players and new entrants; most of these are mid-sized players (43%) based in North America.
• In pursuit of gaining a competitive edge in this field, stakeholders are actively upgrading their existing capabilities and adding new competencies in order to enhance their respective portfolios.
• The ongoing efforts to improve capabilities and upgrade facilities have led to the establishment of industry benchmarks, which serve as a standard for new product development initiatives.

• The growing interest of stakeholders in this domain is evident from the rise in partnership activity; most of the partnerships are focused on antibody manufacturing.
• In order to enhance core competencies related to this field of research, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities.
• The global installed antibody contract manufacturing capacity is spread across various regions; over 55% of this capacity is available in manufacturing facilities based in North America.
• Given that there are several antibody-based drug / therapy candidates being evaluated across various stages of development, the demand for such products is anticipated to rise significantly over the next decade.
• The antibody manufacturing market is likely to grow at a CAGR of 10%, till 2035; presently, majority of the market share is occupied by North America, followed by Europe.

ANTIBODY CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

Monoclonal Antibodies Segment Occupy the Largest Share of the Global Antibody Contract Manufacturing Market

Based on the type of antibody manufactured, the market is segmented into monoclonal and bispecific antibody. At present, the monoclonal antibody segment holds the maximum share of the global antibody contract manufacturing market. However, players are now increasingly focused on the development of bispecific antibodies for therapeutic use.

By Type of Expression System Used, the Microbial Expression System is the Fastest Growing Segment of the Global Antibody Contract Manufacturing Market

Based on the type of expression system used, the market is segmented into mammalian and microbial expression systems. Currently, the mammalian expression system segment captures the highest proportion of the global antibody contract manufacturing market, owing to the fact that mammalian expression systems allow antibodies to produce higher biological activity and binding affinity.

Commercial Segment Occupy the Largest Share of the Global Antibody Contract Manufacturing Market

Based on the scale of operation, the market is segmented into clinical and commercial scales. At present, the commercial segment holds the maximum share of the global antibody contract manufacturing market owing to the increasing demand for commercial production of antibodies.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Latin America and the Middle East and North Africa. Currently, North America dominates the antibody contract manufacturing market and accounts for the largest revenue share. Additionally, the market in Asia is likely to grow at a higher CAGR in the future.

Example Players in the Antibody Contract Manufacturing Market

• AGC Biologics
• Aldevron
• Emergent BioSolutions
• Eurofins CDMO
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Novasep
• Pierre Fabre
• Samsung BioLogics
• Synthon
• Thermo Fisher Scientific

ANTIBODY CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global antibody contract manufacturing market, focusing on key market segments, including [A] type of antibody manufactured, [B] type of expression system used, [C] scale of operation and [D] geographical regions.
• Market Landscape: A comprehensive evaluation of the companies engaged in antibody contract manufacturing market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facilities, [E] scale of operation, [F] type of antibody, [G] type of expression systems used, [H] fill / finish operations and [I] affiliations to regulatory agencies.
• Company Competitiveness Analysis: A comprehensive competitive analysis of antibody contract manufacturers, examining factors, such as [A] company strength and [B] portfolio strength and [C] portfolio diversity.
• Company Profiles: In-depth profiles of key service providers engaged in the antibody contract manufacturing market, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio, and [D] recent developments and an informed future outlook.
• Case Study: A detailed comparison of the key characteristics of large and small molecule drugs, along with information on the steps and challenges involved in their respective manufacturing processes.
• Benchmark Analysis: A detailed analysis of the key focus areas of small, mid-sized, large and very large companies by comparing their existing capabilities within and beyond their respective peer groups.
• Capacity Analysis: An insightful analysis of the overall installed capacity for manufacturing antibodies, based on various parameters, such as [A] company size and [B] key geographical regions.
• Demand Analysis: An in-depth analysis of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength.
• SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of antibody contract manufacturing market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Future Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
    • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Concept of an Antibody
• 5.3. Structure of an Antibody
• 5.4. Antibody Isotypes
• 5.5. Mechanism of Action of Antibodies
• 5.6. Types of Antibodies
  • 5.6.1. Monoclonal Antibodies
  • 5.6.2. Bispecific Antibodies
  • 5.6.3. Polyclonal Antibodies
• 5.7. Overview of Contract Manufacturing
• 5.8. Need for Outsourcing in the Biopharmaceutical Industry
• 5.9. Advantages of Outsourcing Manufacturing Services

6. MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Antibody Contract Manufacturers: Overall Market Landscape
  • 6.2.1. Analysis by Year of Establishment
  • 6.2.2. Analysis by Company Size
  • 6.2.3. Analysis by Location of Headquarters
  • 6.2.4. Analysis by Location of Antibody Manufacturing Facilities
  • 6.2.5. Analysis by Scale of Operation
  • 6.2.6. Analysis by Type of Antibody Manufactured
  • 6.2.7. Analysis by Expression System Used
  • 6.2.8. Analysis by Fill / Finish Services Offered

7. COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Key Input Parameters
• 7.3. Methodology
• 7.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
• 7.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
• 7.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia-Pacific

8. DETAILED COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. AGC Biologics
  • 8.2.1. Company Overview
  • 8.2.2. Antibody Contract Manufacturing Service Portfolio
  • 8.2.3. Recent Developments and Future Outlook
• 8.3. Aldeveron
  • 8.3.1. Company Overview
  • 8.3.2. Antibody Contract Manufacturing Service Portfolio
  • 8.3.3. Recent Developments and Future Outlook
• 8.4. Emergent Biosolutions
  • 8.4.1. Company Overview
  • 8.4.2. Antibody Contract Manufacturing Service Portfolio
  • 8.4.3. Recent Developments and Future Outlook
• 8.5. Eurofins CDMO
  • 8.5.1. Company Overview
  • 8.5.2. Antibody Contract Manufacturing Service Portfolio
  • 8.5.3. Future Outlook
• 8.6. FUJIFILM Diosynth Biotechnologies
  • 8.6.1. Company Overview
  • 8.6.2. Antibody Contract Manufacturing Service Portfolio
  • 8.6.3. Recent Developments and Future Outlook
• 8.7. KBI Biopharma
  • 8.7.1. Company Overview
  • 8.7.2. Antibody Contract Manufacturing Service Portfolio
  • 8.7.3. Recent Developments and Future Outlook
• 8.8. Lonza
  • 8.8.1. Company Overview
  • 8.8.2. Antibody Contract Manufacturing Service Portfolio
  • 8.8.3. Recent Developments and Future Outlook
• 8.9. Nitto Avecia Pharma Services
  • 8.9.1. Company Overview
  • 8.9.2. Antibody Contract Manufacturing Service Portfolio
  • 8.9.3. Recent Developments and Future Outlook
• 8.10. Novasep
  • 8.10.1. Company Overview
  • 8.10.2. Antibody Contract Manufacturing Service Portfolio
  • 8.10.3. Future Outlook
• 8.11. Pierre Fabre
  • 8.11.1. Company Overview
  • 8.11.2. Antibody Contract Manufacturing Service Portfolio
  • 8.11.3. Recent Developments and Future Outlook
• 8.12. Samsung Biologics
  • 8.12.1. Company Overview
  • 8.12.2. Antibody Contract Manufacturing Service Portfolio
  • 8.12.3. Recent Developments and Future Outlook
• 8.13. Synthon
  • 8.13.1. Company Overview
  • 8.13.2. Antibody Contract Manufacturing Service Portfolio
  • 8.13.3. Recent Developments and Future Outlook
• 8.14. Thermo Fisher Scientific
  • 8.14.1. Company Overview
  • 8.14.2. Antibody Contract Manufacturing Service Portfolio
  • 8.14.3. Recent Developments and Future Outlook

9. TABULATED COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. ABL
  • 9.2.1. Company Overview
  • 9.2.2. Antibody Contract Manufacturing Service Portfolio
• 9.3. Abzena
  • 9.3.1. Company Overview
  • 9.3.2. Antibody Contract Manufacturing Service Portfolio
• 9.4. Allele Biotechnology & Pharmaceuticals
  • 9.4.1. Company Overview
  • 9.4.2. Antibody Contract Manufacturing Service Portfolio
• 9.5. Alvotech
  • 9.5.1. Company Overview
  • 9.5.2. Antibody Contract Manufacturing Service Portfolio
• 9.6. Antibody Production Services
  • 9.6.1. Company Overview
  • 9.6.2. Antibody Contract Manufacturing Service Portfolio
• 9.7. Arabio
  • 9.7.1. Company Overview
  • 9.7.2. Antibody Contract Manufacturing Service Portfolio
• 9.8. Bharat Serums and Vaccines
  • 9.8.1. Company Overview
  • 9.8.2. Antibody Contract Manufacturing Service Portfolio
• 9.9. Boehringer Ingelheim
  • 9.9.1. Company Overview
  • 9.9.2. Antibody Contract Manufacturing Service Portfolio
• 9.10. Glenmark Pharmaceuticals
  • 9.10.1. Company Overview
  • 9.10.2. Antibody Contract Manufacturing Service Portfolio
• 9.11. MilliporeSigma
  • 9.11.1. Company Overview
  • 9.11.2. Antibody Contract Manufacturing Service Portfolio
• 9.12. Siam Bioscience
  • 9.12.1. Company Overview
  • 9.12.2. Antibody Contract Manufacturing Service Portfolio

10. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES

• 10.1. Chapter Overview
• 10.2. Small Molecules and Biologics
  • 10.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
  • 10.2.2. Comparison of Key Characteristics
  • 10.2.3. Comparison of Manufacturing Processes
  • 10.2.4. Comparison of Key Manufacturing related Challenges

11. BENCHMARK ANALYSIS

• 11.1. Chapter Overview
• 11.2. Methodology
• 11.3. Antibody Contract Manufacturers: Benchmarking Analysis
  • 11.3.1. Benchmark Analysis of Small Players Based in North America (Peer Group I)
  • 11.3.2. Benchmark Analysis of Mid-Sized Players Based in North America (Peer Group II)
  • 11.3.3. Benchmark Analysis of Large Players Based in North America (Peer Group III)
  • 11.3.4. Benchmark Analysis of Very Large Players Based in North America (Peer Group IV)
  • 11.3.5. Benchmark Analysis of Small Players Based in Europe (Peer Group V)
  • 11.3.6. Benchmark Analysis of Mid-Sized Players Based in Europe (Peer Group VI)
  • 11.3.7. Benchmark Analysis of Large Players Based in Europe (Peer Group VII)
  • 11.3.8. Benchmark Analysis of Very Large Players Based in Europe (Peer Group VIII)
  • 11.3.9. Benchmark Analysis of Small Players Based in Asia-Pacific (Peer Group IX)
  • 11.3.10. Benchmark Analysis of Mid-Sized Players Based in Asia-Pacific (Peer Group X)
  • 11.3.11. Benchmark Analysis of Large Players Based in Asia-Pacific (Peer Group XI)
  • 11.3.12. Benchmark Analysis of Very Large Players Based in Asia-Pacific (Peer Group XII)
• 11.4. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnerships Models
• 12.3. Antibody Contract Manufacturing: List of Partnerships
  • 12.3.1. Analysis by Year of Partnership
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Year and Type of Partnership
  • 12.3.4. Analysis by Type of Antibody Manufactured
  • 12.3.5. Analysis by Project Scale
  • 12.3.6. Analysis by Focus Therapeutic Area
  • 12.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership
  • 12.3.8. Geographical Analysis
    • 12.3.8.1. Continent-wise Distribution
    • 12.3.8.2. Country-wise Distribution

13. RECENT EXPANSIONS

• 13.1. Chapter Overview
• 13.2. Antibody Contract Manufacturers: List of Expansions
  • 13.2.1. Analysis by Year of Expansion
  • 13.2.2. Analysis by Type of Expansion
  • 13.2.3. Analysis by Type of Antibody Manufactured
  • 13.2.4. Analysis by Location of Manufacturing Facility
  • 13.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
  • 13.2.6. Analysis of Most Active Players by Number of Expansions
  • 13.2.7. Geographical Analysis
    • 13.2.7.1. Country-wise Distribution

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Antibody Contract Manufacturing: Installed Global Capacity
  • 14.3.1. Analysis by Scale of Operation
  • 14.3.2. Analysis by Type of Expression System Used
  • 14.3.3. Analysis by Location of Manufacturing Facility
• 14.4. Concluding Remarks

15. DEMAND ANALYSIS

• 15.1. Chapter Overview
• 15.2. Assumptions and Methodology
• 15.3. Antibody Contract Manufacturing Market: Overall Annual Demand
  • 15.3.1. Analysis by Scale of Operation
  • 15.3.2. Analysis by Geography

16 MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges
• 16.6. Conclusion

17 GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Global Antibody Contract Manufacturing Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
  • 17.3.1. Scenario Analysis
    • 17.3.1.1. Conservative Scenario
    • 17.3.1.2. Optimistic Scenario
• 17.4. Key Market Segmentations

18. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY TYPE OF ANTIBODY MANUFCATURED

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured
  • 18.3.1. Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 18.3.2. Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
• 18.4. Data Triangulation and Validation

19. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Antibody Contract Manufacturing Market: Distribution by Scale of Operation
  • 19.3.1. Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 19.3.2. Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
• 19.4. Data Triangulation and Validation

20. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used
  • 20.3.1. Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 20.3.2. Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Antibody Contract Manufacturing Market: Distribution by Key Geographical Regions
  • 21.3.1. Antibody Contract Manufacturing Market in North America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 21.3.2. Antibody Contract Manufacturing Market in Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
  • 21.3.3. Antibody Contract Manufacturing Market in Asia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 21.3.4. Antibody Contract Manufacturing Market in Latin America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
  • 21.3.5. Antibody Contract Manufacturing Market in Middle East and North Africa: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• 21.4. Data Triangulation and Validation

22. SWOT ANALYSIS

• 22.1. Chapter Overview
• 22.2. Strengths
• 22.3. Weaknesses
• 22.4. Opportunities
• 22.5. Threats
• 22.6. Comparison of SWOT Factors
• 22.7. Concluding Remarks

23 FUTURE OF THE ANTIBODY CMO MARKET

• 23.1. Chapter Overview
• 23.2. Rise in Outsourcing Activity
• 23.3. Shift from One-time Contractual Engagements to Strategic Partnerships
• 23.4. Adoption of New and Innovative Technologies
• 23.5. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
• 23.6. Capability and Expertise Expansions by CMOs to become One Stop Shops
• 23.7. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
• 23.8. Challenges Faced by both Sponsors and Service Providers
• 23.9. Factors Influencing the Future of Antibody Contract Manufacturing Market
• 23.10. Concluding Remarks

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
• 24.3. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
• 24.4. Patrica, Business Development and Marketing Manager, 53 Biologics
• 24.5. Daniel, Business Development Manager, EirGenix
• 24.6. Michiel Stork, Business Development Manager, ProBiogen
• 24.7. Judyta Suskiewicz, Business Development Specialist, Mabion

25. APPENDIX 2: TABULATED DATA

26. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS